Expertise in
22
conditions

Dr. Renata Ferrarotto

Oncology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Offers Telehealth
Expertise in
22
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Renata Ferrarotto is an Oncologist practicing medicine in Cary, North Carolina.

Dr. Ferrarotto is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Adenoid Cystic Carcinoma, Anaplastic Thyroid Cancer, Olfactory Neuroblastoma, Thyroidectomy, and Gastrostomy.

She is actively involved in clinical research, co-authoring 222 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

AL101 Prior to Standard-of-Care Surgery in Patients With Notch Activated Adenoid Cystic Carcinoma (ACC)
AL101 Prior to Standard-of-Care Surgery in Patients With Notch Activated Adenoid Cystic Carcinoma (ACC)
Enrollment Status: Completed
Publish Date: June 24, 2026
Intervention Type: Drug, Procedure
Study Drug: AL101
Study Phase: Phase 1
Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP)
Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP)
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Docetaxel, Pembrolizumab
Study Phase: Phase 2
Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Other, Biological
Study Phase: Phase 2
Phase I/II Study of M7824 Plus Curative Intent Re-Irradiation With Stereotactic Body Radiation Therapy (SBRT) in Patients With Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma
Phase I/II Study of M7824 Plus Curative Intent Re-Irradiation With Stereotactic Body Radiation Therapy (SBRT) in Patients With Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: November 07, 2024
Intervention Type: Other, Drug, Radiation
Study Drug: Bintrafusp Alfa
Study Phase: Phase 1/Phase 2
A Phase 2 Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)
A Phase 2 Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)
Enrollment Status: Completed
Publish Date: October 18, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Axitinib
Study Phase: Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)
Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)
Enrollment Status: Completed
Publish Date: March 18, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 6 Less Clinical Trials

222 Total Publications

Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.
Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.
Journal: JAMA network open
Published: July 16, 2026
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Conley is an Oncologist practicing medicine in Cary, North Carolina. Dr. Conley is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Chondrosarcoma, Alveolar Soft Part Sarcoma, Liposarcoma, and Salpingo-Oophorectomy.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Alessandra Ferrajoli is an Oncologist practicing medicine in Cary, North Carolina. Dr. Ferrajoli is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Michelle Fanale is an Oncologist practicing medicine in Cary, North Carolina. Dr. Fanale is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, T-Cell Lymphoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Renata Ferrarotto

How do I make an appointment with Dr. Renata Ferrarotto?

You can book an appointment with Dr. Renata Ferrarotto by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Renata Ferrarotto a top-rated expert for Adenoid Cystic Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Renata Ferrarotto is classified as an Elite expert for Adenoid Cystic Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Renata Ferrarotto specialize in?

While Dr. Renata Ferrarotto is a Oncology, they have specific expertise in Adenoid Cystic Carcinoma, Anaplastic Thyroid Cancer, and Olfactory Neuroblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Renata Ferrarotto participate in research or clinical trials?

Yes. Dr. Renata Ferrarotto has published 222 articles and abstracts on conditions like Adenoid Cystic Carcinoma. You can view a list of Dr. Renata Ferrarotto's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Renata Ferrarotto accept my insurance?

Dr. Renata Ferrarotto accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ferrarotto's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 9 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile